Back
Rate this talk
Your peers have not rated this talk yet.
18-minute watch | Talk 2 of 4

EHA: Follow the patient pathway to survival in 2L DLBCL

Choosing CAR T with curative intent

Dr Natasha Kekre
SYMPOSIUM
EHA

Dr Natasha Kekre
The Ottawa Hospital, Ottawa, Ontario, Canada

Dr Natasha Kekre of The Ottawa Hospital, Ottawa, Ontario, Canada reviews clinical trial data and real-world evidence for CAR T in 2L DLBCL, highlighting the importance of early referral

Read more

Talks in this series

Dr Bastos-Oreiro presents at EHA (Planning ahead for 2L)
23-minute watch | Talk 1 of 4
EHA: Follow the patient pathway to survival in 2L DLBCL
Planning ahead for 2L
Dr Bastos-Oreiro presents at EHA (Planning ahead for 2L)
23-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL

Planning ahead for 2L

Dr Kekre presents at EHA (Choosing CAR T with curative intent)
18-minute watch | Talk 2 of 4
Choosing CAR T with curative intent
Dr Natasha Kekre
Dr Kekre presents at EHA (Choosing CAR T with curative intent)
18-minute watch

Choosing CAR T with curative intent

Dr Natasha Kekre

Dr Sesques presents at EHA (Delivering CAR T)
10-minute watch | Talk 3 of 4
Delivering CAR T
Dr Pierre Sesques
Dr Sesques presents at EHA (Delivering CAR T)
10-minute watch

Delivering CAR T

Dr Pierre Sesques

Dr Sesques presents at EHA (CAR T survivorship and summary)
13-minute watch | Talk 4 of 4
CAR T survivorship and summary
Prof. Graham Collins, Dr Mariana Bastos-Oreiro, Dr Pierre Sesques
Dr Sesques presents at EHA (CAR T survivorship and summary)
13-minute watch

CAR T survivorship and summary

Prof. Graham Collins, Dr Mariana Bastos-Oreiro, Dr Pierre Sesques

Dr Bastos-Oreiro presents at EHA (Planning ahead for 2L)
23-minute watch | Talk 1 of 4
EHA: Follow the patient pathway to survival in 2L DLBCL
Planning ahead for 2L
Dr Bastos-Oreiro presents at EHA (Planning ahead for 2L)
23-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL

Planning ahead for 2L

Dr Kekre presents at EHA (Choosing CAR T with curative intent)
18-minute watch | Talk 2 of 4
Choosing CAR T with curative intent
Dr Natasha Kekre
Dr Kekre presents at EHA (Choosing CAR T with curative intent)
18-minute watch

Choosing CAR T with curative intent

Dr Natasha Kekre

Dr Sesques presents at EHA (Delivering CAR T)
10-minute watch | Talk 3 of 4
Delivering CAR T
Dr Pierre Sesques
Dr Sesques presents at EHA (Delivering CAR T)
10-minute watch

Delivering CAR T

Dr Pierre Sesques

Dr Sesques presents at EHA (CAR T survivorship and summary)
13-minute watch | Talk 4 of 4
CAR T survivorship and summary
Prof. Graham Collins, Dr Mariana Bastos-Oreiro, Dr Pierre Sesques
Dr Sesques presents at EHA (CAR T survivorship and summary)
13-minute watch

CAR T survivorship and summary

Prof. Graham Collins, Dr Mariana Bastos-Oreiro, Dr Pierre Sesques

Interested in this topic?

Find more like this

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.